Multivalent thioether-peptide conjugates: B cell tolerance of an anti-peptide immune response

Area of Science:

• Immunology
• Autoimmunity
• Drug Development

Background:

• Antibodies against beta2-glycoprotein I (beta2GPI) are key players in antiphospholipid syndrome.
• Synthetic peptide mimotopes offer a strategy to block these pathogenic antibodies.

Purpose of the Study:

• To develop and test novel tetravalent peptide-platform conjugates as B cell toleragens.
• To evaluate the efficacy of these conjugates in suppressing anti-beta2GPI antibody production.

Main Methods:

• Synthesized and modified two cyclic thioether peptide mimotopes (peptides 1a and 1b) with thiol-containing linkers.
• Created four tetravalent peptide-platform conjugates and peptide-KLH conjugates for immunization.
• Administered conjugates to mice to assess their ability to suppress anti-peptide antibody formation.

Main Results:

• Three out of four tetravalent peptide-platform conjugates successfully suppressed anti-peptide antibody formation in immunized mice.
• Conjugate stability in mouse serum was assessed but did not correlate with tolerogenic efficacy.

Conclusions:

• Tetravalent peptide conjugates can act as effective B cell toleragens, suppressing pathogenic antibody responses.
• This approach holds potential for treating autoimmune diseases like antiphospholipid syndrome.